RxDoctor Payments Data

Paola Greiger-Zanlungo, MD

Internal Medicine · Mount Vernon, NYNPI 1306824339

Payments from drug & device makers

$20,408in general payments, 2019–2025

Across 297 payments — averaging $68.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$17K
  • Johnson & Johnson$2K
  • Viiv Healthcare Company$811
  • Janssen Products, LP$224
  • AbbVie$215
  • Merck$201
  • plus $388 from 7 others
$2,500in research payments, 2019–2025

Across 1 payment — averaging $2500.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Gilead$3K

What the payments were for

  • Speaking & faculty fees$12,47061%
  • Travel & lodging$1,3827%
  • Food & beverage$6,33231%
  • Education$2241%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,408 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$8,417
Medicare patients
28
Services billed
85

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala128$495,471
JulucaDolutegravir/Rilpivirine101$365,047
TriumeqAbacavir/Dolutegravir/Lamivudi42$155,066
TivicayDolutegravir Sodium25$55,965
EliquisApixaban75$45,156
PrezcobixDarunavir/Cobicistat18$44,079
EntrestoSacubitril/Valsartan50$32,744
JardianceEmpagliflozin11$20,183
JanuviaSitagliptin Phosphate27$18,085
TrulicityDulaglutide16$15,262
OzempicSemaglutide14$12,640
TradjentaLinagliptin13$10,223
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$9,763
RestasisCyclosporine17$9,707
MyrbetriqMirabegron11$4,698

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyJuluca, Triumeq, Tivicay$811$576,078168 claims
GileadBiktarvy$16,720$495,471128 claims
Johnson & JohnsonPrezcobix$1,849$44,07918 claims
NovartisEntresto$23$32,74450 claims
MerckJanuvia$201$18,08527 claims
AbbVieRestasis$215$9,70717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Mount Vernon

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →